search
Back to results

Continuous Passive Motion Versus Heterotopic Ossification (CPMversusHO)

Primary Purpose

Traumatic Brain Injury, Spinal Cord Injuries, Stroke

Status
Recruiting
Phase
Not Applicable
Locations
Greece
Study Type
Interventional
Intervention
Continuous Passive Motion (CPM)
Conventional physiotherapy (PT)
Zoledronic Acid Injection
Sponsored by
University of Ioannina
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Traumatic Brain Injury focused on measuring Ossification, Heterotopic, continuous passive motion (CPM), zoledronic acid, range of motion (ROM), PROPHYLAXIS

Eligibility Criteria

15 Years - 70 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with stabilized medical condition suffering from neurological insult either traumatic brain injury (TBI), stroke, or Spinal Cord Injury. A negative triplex ultrasound in order to rule out deep venous thrombosis (DVT) A positive three-phase bone scan with Tc99. (Will be obtained as soon as HO symptoms are onset.) Patients with verified HO formation on the knee or hip joint will undergo a CT to show the extent of the lesion. Exclusion Criteria: Life-threatening conditions that render Continuous passive motion (CPM) application difficult. HO detected in another location than the hip or knee joint. Concomitantly presence of other fractures that will interfere with the bone alkaline phosphatase (AP) level. Patients not reacting to painful stimuli

Sites / Locations

  • Department of Physical and Rehabilitation MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Continuous passive motion (CPM)

Physiotherapy (PT)

Arm Description

10 ICU patients receiving CPM at HO joints that continuously stretches slowly the joint passively at a constant velocity in a painless range and for a substantial amount of time until there is evidence both laboratory (bone alkaline phosphatase) and radiographically (CT), that osteogenesis has entered a quiescent state. Conventional PT will also be performed. Plus a single dose of zoledronic acid (Aclasta) once the diagnosis of HO is made.

10 ICU patients receiving the conventional PT, plus a single dose of zoledronic acid (Aclasta) once the diagnosis of HO is made.

Outcomes

Primary Outcome Measures

ROM lost during the trial
The difference in ROM between the measurements at baseline and at the end of the The program will last until there is evidence by CT and laboratory measurements (bone Alkaline Phosphatase) that osteogenesis has entered a quiescent state. prophylactic program
HO appearance on CT
Based on Brooker HO classification method (between I and IV with IV being bridging bone and joint ankylosis), the difference in CT appearance at baseline and at the end of the program will serve as a descriptive tool. Until there is evidence by CT and laboratory measurements (bone Alkaline Phosphatase) that osteogenesis has entered a quiescent state.

Secondary Outcome Measures

Patient's Glasgow Coma Scale (GCS)
Calculation of GCS (range 0-15 with 15 being the normal) at the beginning and at the end of the CPM program.Until there is evidence by CT and laboratory measurements (bone Alkaline Phosphatase) that osteogenesis has entered a quiescent state.

Full Information

First Posted
May 8, 2023
Last Updated
June 16, 2023
Sponsor
University of Ioannina
search

1. Study Identification

Unique Protocol Identification Number
NCT05906056
Brief Title
Continuous Passive Motion Versus Heterotopic Ossification
Acronym
CPMversusHO
Official Title
Program of Continuous Passive Motion Exercises Against Heterotopic Ossification
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 12, 2023 (Actual)
Primary Completion Date
April 25, 2026 (Anticipated)
Study Completion Date
March 25, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Ioannina

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigators hypothesize that Heterotopic Ossification (HO) formation can be suppressed if the application of a Continuous Passive Motion (CPM) device can be performed for a substantial amount of time. The investigators will use the following study design: a pilot study with 10 ICU patients receiving CPM and 10 matched cases which will follow a conventional physiotherapy program at the time of the conduction of the study. The comparison between the treatment and referent groups of the outcomes will prove the prophylactic power of CPM against HO.
Detailed Description
The aim of this study is to formally evaluate whether the investigators can indeed prevent HO by the timely and painless use of CPM in neurogenic intensive care unit (ICU) patients with stabilized medical conditions, suffering from neurological insults either traumatic brain injury (TBI), stroke, or Spinal Cord Injury (SCI). The investigators hypothesize that HO formation can be suppressed if CPM can be performed for a substantial amount of time. The investigators will perform a pilot study with 10 ICU patients receiving CPM and 10 matched cases which will follow a conventional physiotherapy program at the time of the conduction of the study. The primary outcomes will be the CT appearance of HO in the hip or knee joint and the degree of ROM limitation in the given joint at baseline and at the end of the clinical trial. A secondary outcome that will be measured, will be the Glasgow Coma Scale (GCS) at the beginning and at the end of the CPM program. The comparison between the treatment and referent groups in terms of these outcomes will prove the prophylactic power of CPM against HO.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Traumatic Brain Injury, Spinal Cord Injuries, Stroke
Keywords
Ossification, Heterotopic, continuous passive motion (CPM), zoledronic acid, range of motion (ROM), PROPHYLAXIS

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
randomized control trial
Masking
Outcomes Assessor
Masking Description
CT will not reveal the group of patient's origin to the reader
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Continuous passive motion (CPM)
Arm Type
Experimental
Arm Description
10 ICU patients receiving CPM at HO joints that continuously stretches slowly the joint passively at a constant velocity in a painless range and for a substantial amount of time until there is evidence both laboratory (bone alkaline phosphatase) and radiographically (CT), that osteogenesis has entered a quiescent state. Conventional PT will also be performed. Plus a single dose of zoledronic acid (Aclasta) once the diagnosis of HO is made.
Arm Title
Physiotherapy (PT)
Arm Type
Active Comparator
Arm Description
10 ICU patients receiving the conventional PT, plus a single dose of zoledronic acid (Aclasta) once the diagnosis of HO is made.
Intervention Type
Device
Intervention Name(s)
Continuous Passive Motion (CPM)
Intervention Description
CPM uses machines to move a joint passively i.e. without the patient exerting any effort. A motorized device moves the joint repetitively to a set of degrees and movement speed, determined by the caregiver either a medical doctor (physiatrist or orthopedic surgeon) or a physiotherapist. Its action preserves the joint's range of motion (ROM)
Intervention Type
Other
Intervention Name(s)
Conventional physiotherapy (PT)
Intervention Description
Daily passive range of motion exercises (ROM) performed by the physiotherapist of the intensive care unit (ICU)
Intervention Type
Drug
Intervention Name(s)
Zoledronic Acid Injection
Intervention Description
one dose of intravenous zoledronic acid will be administered
Primary Outcome Measure Information:
Title
ROM lost during the trial
Description
The difference in ROM between the measurements at baseline and at the end of the The program will last until there is evidence by CT and laboratory measurements (bone Alkaline Phosphatase) that osteogenesis has entered a quiescent state. prophylactic program
Time Frame
According to the literature it is estimated to last approx. 70 days
Title
HO appearance on CT
Description
Based on Brooker HO classification method (between I and IV with IV being bridging bone and joint ankylosis), the difference in CT appearance at baseline and at the end of the program will serve as a descriptive tool. Until there is evidence by CT and laboratory measurements (bone Alkaline Phosphatase) that osteogenesis has entered a quiescent state.
Time Frame
According to the literature it is estimated to last approx. 70 days
Secondary Outcome Measure Information:
Title
Patient's Glasgow Coma Scale (GCS)
Description
Calculation of GCS (range 0-15 with 15 being the normal) at the beginning and at the end of the CPM program.Until there is evidence by CT and laboratory measurements (bone Alkaline Phosphatase) that osteogenesis has entered a quiescent state.
Time Frame
According to the literature it is estimated to last approx. 70 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with stabilized medical condition suffering from neurological insult either traumatic brain injury (TBI), stroke, or Spinal Cord Injury. A negative triplex ultrasound in order to rule out deep venous thrombosis (DVT) A positive three-phase bone scan with Tc99. (Will be obtained as soon as HO symptoms are onset.) Patients with verified HO formation on the knee or hip joint will undergo a CT to show the extent of the lesion. Exclusion Criteria: Life-threatening conditions that render Continuous passive motion (CPM) application difficult. HO detected in another location than the hip or knee joint. Concomitantly presence of other fractures that will interfere with the bone alkaline phosphatase (AP) level. Patients not reacting to painful stimuli
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Avraam Ploumis, MD, PhD
Phone
+ 30 693 2080701
Email
aploumis@uoi.gr
First Name & Middle Initial & Last Name or Official Title & Degree
George I Vasileiadis, MD, PhD
Phone
+ 30 694 5789239
Email
givasileiadis@gmail.com
Facility Information:
Facility Name
Department of Physical and Rehabilitation Medicine
City
Ioánnina
State/Province
Epirus
ZIP/Postal Code
45110
Country
Greece
Individual Site Status
Recruiting

12. IPD Sharing Statement

Citations:
PubMed Identifier
12872776
Citation
Scalzitti DA. Because of the risk of developing heterotopic ossification, are passive range of motion exercises contraindicated following traumatic injuries? Phys Ther. 2003 Jul;83(7):659-7. No abstract available.
Results Reference
background
PubMed Identifier
34310347
Citation
Vasileiadis GI, Varvarousis DN, Manolis I, Ploumis A. The Impact of Continuous Passive Motion on Heterotopic Ossification Maturation. Am J Phys Med Rehabil. 2021 Dec 1;100(12):e194-e197. doi: 10.1097/PHM.0000000000001852.
Results Reference
background
PubMed Identifier
35512120
Citation
Vasileiadis GI, Balta AA, Zerva A, Kontogiannopoulos V, Varvarousis DN, Dimakopoulos G, Ploumis A. Role of Kinesiotherapy in the Prevention of Heterotopic Ossification: A Systematic Review. Am J Phys Med Rehabil. 2023 Feb 1;102(2):110-119. doi: 10.1097/PHM.0000000000002043. Epub 2022 Apr 28.
Results Reference
background
PubMed Identifier
22495100
Citation
Genet F, Chehensse C, Jourdan C, Lautridou C, Denormandie P, Schnitzler A. Impact of the operative delay and the degree of neurologic sequelae on recurrence of excised heterotopic ossification in patients with traumatic brain injury. J Head Trauma Rehabil. 2012 Nov-Dec;27(6):443-8. doi: 10.1097/HTR.0b013e31822b54ba.
Results Reference
background
PubMed Identifier
21321512
Citation
van Kampen PJ, Martina JD, Vos PE, Hoedemaekers CW, Hendricks HT. Potential risk factors for developing heterotopic ossification in patients with severe traumatic brain injury. J Head Trauma Rehabil. 2011 Sep-Oct;26(5):384-91. doi: 10.1097/HTR.0b013e3181f78a59.
Results Reference
background
PubMed Identifier
22614800
Citation
Citak M, Suero EM, Backhaus M, Aach M, Godry H, Meindl R, Schildhauer TA. Risk factors for heterotopic ossification in patients with spinal cord injury: a case-control study of 264 patients. Spine (Phila Pa 1976). 2012 Nov 1;37(23):1953-7. doi: 10.1097/BRS.0b013e31825ee81b.
Results Reference
background
PubMed Identifier
11884494
Citation
Shehab D, Elgazzar AH, Collier BD. Heterotopic ossification. J Nucl Med. 2002 Mar;43(3):346-53.
Results Reference
background
PubMed Identifier
8675505
Citation
Holguin PH, Rico AA, Garcia JP, Del Rio JL. Elbow anchylosis due to postburn heterotopic ossification. J Burn Care Rehabil. 1996 Mar-Apr;17(2):150-4. doi: 10.1097/00004630-199603000-00009.
Results Reference
background
PubMed Identifier
11475483
Citation
Linan E, O'Dell MW, Pierce JM. Continuous passive motion in the management of heterotopic ossification in a brain injured patient. Am J Phys Med Rehabil. 2001 Aug;80(8):614-7. doi: 10.1097/00002060-200108000-00013.
Results Reference
background
PubMed Identifier
806274
Citation
Stover SL, Hataway CJ, Zeiger HE. Heterotopic ossification in spinal cord-injured patients. Arch Phys Med Rehabil. 1975 May;56(5):199-204.
Results Reference
background

Learn more about this trial

Continuous Passive Motion Versus Heterotopic Ossification

We'll reach out to this number within 24 hrs